Santosuosso Michael, McCormick Sarah, Roediger Elizabeth, Zhang Xizhong, Zganiacz Anna, Lichty Brian D, Xing Zhou
Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Center for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
J Immunol. 2007 Feb 15;178(4):2387-95. doi: 10.4049/jimmunol.178.4.2387.
Genetic immunization holds great promise for future vaccination against mucosal infectious diseases. However, parenteral genetic immunization is ineffective in control of mucosal intracellular infections, and the underlying mechanisms have remained unclear. By using a model of parenteral i.m. genetic immunization and pulmonary tuberculosis (TB), we have investigated the mechanisms that determine the failure and success of parenteral genetic immunization. We found that lack of protection from pulmonary Mycobacterium tuberculosis (M.tb) challenge by i.m. immunization with a recombinant adenovirus-vectored tuberculosis vaccine was linked to the absence of M.tb Ag-specific T cells within the airway lumen before M.tb challenge despite potent T cell activation in the systemic compartments. Furthermore, pulmonary mycobacterial challenge failed to recruit CD8 T cells into the airway lumen of i.m. immunized mice. Such defect in T cell recruitment, intra-airway CTL, and immune protection was restored by creating acute inflammation in the airway with inflammatory agonists such as virus. However, the Ag-specific T cells recruited as such were not retained in the airway lumen, resulting in a loss of protection. In comparison, airway exposure to low doses of soluble M.tb Ags not only recruited but retained Ag-specific CD8 T cells in the airway lumen over time that provided robust protection against M.tb challenge. Thus, our study reveals that mucosal protection by parenteral immunization is critically determined by T cell geography, i.e., whether Ag-specific T cells are within or outside of the mucosal lumen and presents a feasible solution to empower parenteral immunization strategies against mucosal infectious diseases.
基因免疫在未来针对黏膜感染性疾病的疫苗接种方面具有巨大潜力。然而,肠胃外基因免疫在控制黏膜细胞内感染方面无效,其潜在机制仍不清楚。通过使用肠胃外肌肉注射基因免疫和肺结核(TB)模型,我们研究了决定肠胃外基因免疫成败的机制。我们发现,用重组腺病毒载体结核疫苗进行肌肉注射免疫,无法保护小鼠免受肺部结核分枝杆菌(M.tb)攻击,这与在M.tb攻击前气道腔内缺乏M.tb抗原特异性T细胞有关,尽管在全身各部位T细胞被有效激活。此外,肺部分枝杆菌攻击未能将CD8 T细胞招募到肌肉注射免疫小鼠的气道腔内。通过用病毒等炎性激动剂在气道中引发急性炎症,可恢复T细胞招募、气道内CTL及免疫保护方面的这种缺陷。然而,如此招募的抗原特异性T细胞并未保留在气道腔内,导致保护作用丧失。相比之下,气道暴露于低剂量可溶性M.tb抗原不仅能随着时间推移在气道腔内招募并保留抗原特异性CD8 T细胞,还能提供强大的抗M.tb攻击保护作用。因此,我们的研究表明,肠胃外免疫的黏膜保护作用关键取决于T细胞的分布位置,即抗原特异性T细胞是否在黏膜腔内,这为增强针对黏膜感染性疾病的肠胃外免疫策略提供了一个可行的解决方案。